Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort

Frederique St-Pierre, Stephen Broski, Zequn Sun, Masha Kocherginsky, Andrew Quon, Lucia Baratto, Hatice Savas, Lale Kostakoglu, Jane N. Winter, Thomas E. Witzig, Brad S. Kahl, Andrew Matthew Evens, Leo I. Gordon

Blood (2022) 140 (Supplement 1): 6480–6481.

https://doi.org/10.1182/blood-2022-162114

Published: 2022

Journal Articles

A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408

Fangxin Hong, PhD, Andrew M. Evens, DO, MSc, Paul J Novotny, M.S., Thomas M. Habermann, MD, Ranjana H Advani, MD, Randy D. Gascoyne, MD, Thomas E. Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Amylou C. Dueck, PhD, Brad S Kahl, MD, Gita Thanarajasingam, MD

Blood (2018) 132 (Supplement 1): 4157.

https://doi.org/10.1182/blood-2018-99-117249

Published: 2018

Journal Articles

The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study

Lucia Baratto, MD, Opeyemi Jegede, PhD, Fangxin Hong, PhD, Thomas M. Habermann, MD, Ranjana Advani, MD, Randy D. Gascoyne, MD, Lale Kostakoglu, MD, Thomas E. Witzig, MD, Erik A. Ranheim, MD PhD, Brad S Kahl, MD, Andrew Quon, MD, Andrew M. Evens, DO, MSc

Blood (2018) 132 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2018-99-113247

Published: 2018

Journal Articles

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

Andrew M Evens, DO,MSc, Fangxin Hong, PhD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Randy D. Gascoyne, MD, Thomas E Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Puneet Cheema, MD, Philip Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Terrence Paul Cescon, Julie Chang, MD, Brad S Kahl, MD

Blood (2017) 130 (Supplement 1): 482.

https://doi.org/10.1182/blood.V130.Suppl_1.482.482

Published: 2017

Journal Articles

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Lode J. Swinnen, Hailun Li, MS, Andrew Quon, MD, Randy D. Gascoyne, MD, Erik A. Ranheim, MD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 687.

https://doi.org/10.1182/blood.V120.21.687.687

Published: 2012

Journal Articles

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

Sandra J. Horning, Malik E. Juweid, Heiko Schöder, Gregory Wiseman, Alex McMillan, Lode J. Swinnen, Ranjana Advani, Randy Gascoyne, Andrew Quon

Blood (2010) 115 (4): 775–777.

https://doi.org/10.1182/blood-2009-08-234351

Published: 2010

Journal Articles

Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404

Sandra J. Horning, MD, Malik E. Juweid, MD, Heiko Schoder, Gregory Wiseman, MD, Alex McMillan, Ph.D., Lode J. Swinnen, MBChB, Ranjana Advani, MD, Randy D. Gascoyne, MD, Andrew Quon

Blood (2008) 112 (11): 372.

https://doi.org/10.1182/blood.V112.11.372.372

Published: 2008

Journal Articles

Marked Improvement in Staging Accuracy in Mycosis Fungoides/Sézary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography (PET/CT).

Eunice Y. Tsai, MD, Alan Taur, MD, Leandro Espinosa, MD, Andrew Quon, MD, Sarah E. Dick, MD, Steve Chow, MD, Ranjana Advani, MD, Roger A. Warnke, MD, Sabine Kohler, MD, Richard T. Hoppe, MD, Youn H. Kim, MD

Blood (2004) 104 (11): 3127.

https://doi.org/10.1182/blood.V104.11.3127.3127

Published: 2004

NARROW

FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort

A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408

The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404

Marked Improvement in Staging Accuracy in Mycosis Fungoides/Sézary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography (PET/CT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only